Clinical Trial Update: YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating YM598 added to mitoxantrone/prednisone for pain control in metastatic hormone-refractory prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Mitoxantrone (mitoxantrone)
• PREDNISONE (Prednisone)
• YM598

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Hormone-Refractory Prostate Cancer, Prostatic Neoplasms | Phase 2 | Status: TERMINATED